Maroun Tawk, MD
Pulmonary Disease · Oklahoma City, OKNPI 1255300927
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $49,305 of the $61,540 with a category attached, or 80.1%. Boehringer Ingelheim accounts for 69.9% of it on its own, with 50 other manufacturers making up the rest. Reporting peaked in 2019 at $39,081 and has fallen 93.2% since, to $2,643 in 2025. Among pulmonary disease clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 637 payments — averaging $96.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$43K
- Pfizer$5K
- E.r. Squibb & Sons, L.L.C.$4K
- Insmed, Inc.$1K
- AstraZeneca$1K
- GSK$1K
- plus $6K from 45 others
What the payments were for
- Consulting fees$3461%
- Speaking & faculty fees$49,30580%
- Food & beverage$11,52719%
- Education$3631%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$61,540 in reported general payments places this provider in the 95th percentile of 133 pulmonary disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 163 | $154,388 |
| Fasenra PenBenralizumab | 15 | $90,790 |
| NucalaMepolizumab | 12 | $46,132 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 50 | $34,670 |
| SunosiSolriamfetol Hcl | 17 | $27,351 |
| BelsomraSuvorexant | 43 | $19,010 |
| Spiriva RespimatTiotropium Bromide | 27 | $18,547 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $17,367 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $15,814 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 20 | $8,951 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $5,831 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $5,046 |
| Modafinil | 95 | $4,868 |
| Eszopiclone | 209 | $3,648 |
| Arnuity ElliptaFluticasone Furoate | 12 | $2,820 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $1,015 | $224,985234 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $43,015 | $62,16897 claims |
| Axsome Therapeutics, Inc.Sunosi | $151 | $27,35117 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,125 | $22,41336 claims |
| MerckBelsomra | $207 | $19,01043 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 133 pulmonary disease providers in Oklahoma.
Other pulmonary disease in Oklahoma City
- John KingreyOklahoma City$332K
- Fawad ChaudryOklahoma City$80K
- Nathaniel MoultonOklahoma City$28K
- Syed NaqviOklahoma City$15K
- Tarek DernaikaOklahoma City$12K
- Shoab NazirOklahoma City$11K
- Mark GodishOklahoma City$11K
- Mazen ZouwayhedOklahoma City$10K
- Shoaib AhmadOklahoma City$8K
- Azhar KhanOklahoma City$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.